Molecular Formula | C35H35ClNNaO3S |
Molar Mass | 608.17 |
Melting Point | 115 °C(dec.) |
Boling Point | 750.5°C at 760mmHg |
Specific Rotation(α) | [α]/D +90 to +106° in methanol (c=1) |
Solubility | DMSO: ≥8mg/mL at 60°C |
Appearance | White, brown powder |
Color | white to tan |
Merck | 14,6258 |
Storage Condition | 2-8°C |
Stability | Stable for 1 year from date of purchase as supplied. Solutions in DMSO, distilled water, or ethanol may be stored at -20°C for up to 1 month. |
MDL | MFCD00931431 |
In vitro study | Montelukast is a leukotriene receptor antagonist (LTRA) used for the continuous treatment of asthma and for the relief of seasonal allergic symptoms. Montelukast blocks the action of leukotriene D4 by binding to cysteinyl leukotriene receptor CysLT1 in the lungs and bronchi, preventing airway edema, smooth muscle contraction, and Secretory fluid viscosity. This reduces bronchoconstriction caused by Leukotrienes and makes inflammation less likely. |
In vivo study | Montelukast (6 mg/kg once daily for 20 days) significantly inhibited the increased eosinophils in the BAL fluid and lung tissue of OVA-challenged mice and increased IL-5 levels in the BAL fluid. OVA challenge increases the cyslts receptor but decreases the mRNA expression of the CysLT2 receptor. Upon OVA challenge, Montelukast inhibited increased CysLT1 but did not reduce CysLT2 expression. |
Hazard Symbols | Xi - Irritant |
Risk Codes | R63 - Possible risk of harm to the unborn child R41 - Risk of serious damage to eyes R62 - Possible risk of impaired fertility |
Safety Description | 26 - In case of contact with eyes, rinse immediately with plenty of water and seek medical advice. |
WGK Germany | 3 |
RTECS | GZ0698000 |
HS Code | 2933492250 |